Hi,
The comments in the 4c from McColl are rather positive.
$6 plus mill in this quarter on trials means they are really progressing.
Also its the first time Ive heard him say they are responding to the large pharmas in relation to trial type and design. Sounds very positive.
Stock is a buy .imo.
Aloha.